Investments Plan 2026
BIASCA, Switzerland • January 13th, 2026 • HAS Healthcare Advanced Synthesis SA Group announces strategic investment plan to strengthen leadership in CDMO and ADC manufacturing. Download the Press Release
Read more
New Sustainability Report
LUGANO, Switzerland • September 4th, 2025 • At Cerbios-Pharma SA, we are fully committed to integrating sustainable practices into every aspect of our operations, recognizing our responsibility towards the environment and the communities we serve. In line with this ongoing commitment, we are proud to publish our latest Sustainability Report, detailing our key efforts in…
HAS Healthcare Advanced Synthesis completes the acquisition of Cerbios
LUGANO, Switzerland • May 7th, 2025 • HAS Healthcare Advanced Synthesis SA completes the acquisition of Cerbios-Pharma SA to establish a top-tier global group in the CDMO industry, backed by 65 Equity Partners. Download the Press Release
HAS acquires Cerbios-Pharma SA
LUGANO, Switzerland • March 31th, 2025 • Today we are proud to announce that Cerbios-Pharma SA, Switzerland and HAS Advanced Synthesis SA, Switzerland (HAS), are joining their forces. Download the Press Release
Cerbios-Pharma S.A. Boosts Production Capabilities for HPAPIs and ADCs
LUGANO, Switzerland • February 28th, 2025 • Cerbios-Pharma is proud to announce the opening of a new expansion area at the Lugano site for clinical and commercial manufacturing of Highly Potent Active Pharmaceutical Ingredients (HPAPIs), including cytotoxic linker payloads for antibody-drug conjugates (ADCs). The inauguration was conducted in the presence of Christian Suà, CEO of…
Cerbios-Pharma Commits to Sustainability with New Solar Panel Installation in Lugano
LUGANO, Switzerland • April 8th, 2024 • Cerbios-Pharma SA is proud to announce the completion of a photovoltaic power plant at its Lugano site. This new milestone marks a significant step forward in the Company’s commitment to environmental protection and sustainability, further to last year’s implementation of a new solvent collection and separation process which…
HPAPI and ADC payload manufacturing capacity expansion
LUGANO, Switzerland • May 10th, 2023 • During our long standing 45 years history in the pharmaceutical industry, as Cerbios-Pharma, we have always invested in expanding our capabilities and in the last years more and more resources were addressed to support our customers with innovative CDMO services for HPAPIs and ADCs. Today, we are pleased…
New additional R&D laboratory unit
LUGANO, Switzerland • May 31th, 2022 • Cerbios-Pharma SA announces the opening, at its Lugano site, of an additional R&D laboratory unit equipped with state-of-the-art technologies. This new space will host an area for the development activities related to Highly Potent Molecules and a separate section for the analytical support of CDMO projects. These laboratories, designed…
Pharma Tech Outlook – Top 10 EU CMO’s 2022 – Cerbios Cover Story (April 2022)
LUGANO, Switzerland • April 13th, 2022 • We are proud to announce that Pharma Tech Outlook named Cerbios as Top CMO for 2022. A panel of experts and members of Pharma Tech Outlook’s editorial board defined the pool of companies noteworthy in 2022 and our innovating end-to-end services were evaluated as worth to gain the magazine cover story…
Cerbios announces the near finalization of a new cGMP unit for cytotoxic, a further step towards HPAPIs and ADCs market needs
LUGANO, Switzerland • April 13th, 2022 • Swiss based Cerbios-Pharma SA, specialized in the development and manufacturing of chemical and biotechnological APIs, is officially announcing the near finalization of the structure for its new manufacturing building dedicated to High Potency Active Ingredients (HPAPI), which will host 2 additional cGMP production lines for Cytotoxic molecules and additional…
Welcome to the new normality
LUGANO, Switzerland • Spring 2022 marked the beginning for Cerbios of a year full of events, finally live. DCAT The kick-off was represented by DCAT, a perfect occasion to update our US partners about the latest improvements in Cerbios capabilities and introduce the recently reorganized Business Team structure: Dr Vítor Sousa – BD Manager for ADCs…
CPhI Milan 2021 – in Cerbios we have clearly in minds what Innovation does mean!
LUGANO, Switzerland • As a pharmaceutical Company, Cerbios is devoted continuously to Innovation: building on our vast experience, we are now ready to jump into the future for the next step development. Probiotics as Pharmaceutical Drug Product For more than 40 years, Cerbios has been manufacturing and commercializing its proprietary strain E. faecium SF68® as a…
CPHI Milan 2021 – Welcome back to the Live Event
LUGANO, Switzerland • Continuous improvement and Innovation are part of the Cerbios DNA, and today, more than ever, a focal point of the Company is Lean Management. Applying Lean principles means working proactively, and the rewards are long lasting both for the Company and its Customers. In line with this simplified approach and to be closer to market…
Restructured Proveo one stop shop for pharma Antibody Drug Conjugates (ADCs)
LUGANO, Switzerland • The Proveo offer of a “one-stop-shop” for Antibody Drug Conjugate (ADC) development, manufacturing and delivery is now restructured as a fully integrated business division of Cerbios-Pharma SA. The restructuring ensures that the service can meet the complex supply chain and program management requirements for successful ADC Drug Product manufacturing, allowing it to provide a…
Cerbios presenting benefits of restructured PROVEO service at the World ADC 2021
LUGANO, Switzerland • Pharmaceutical CDMO specialist Cerbios-Pharma SA (Cerbios) will again be a key presence at the 12th World ADC conference Digital San Diego Edition happening from the .11th to the 14th October. Cerbios will be presenting its Proveo division in the CMC stream and in the virtual booth promoting advanced integrated solutions in antibody drug conjugates.…
CERBIOS NEW HPAPI PRODUCTION PLANT APPROVED BY SWISSMEDIC
LUGANO, June 28th, 2021 • Swissmedic approved Cerbios’ new HPAPI plant Cerbios-Pharma is pleased to announce the approval by Swissmedic of its new HPAPI plant, which forms the latest addition to its plan of expansion into the manufacture of highly potent drug substances. This new production line is dedicated to highly active products with containment…
NEW 400 MHZ NMR IN CERBIOS
LUGANO, April 7th, 2020 • From April 1st 2020 the 400 MHz NMR is fully operational in Cerbios. The new equipment expands Cerbios’s already outstanding analytical chemistry capabilities, which now comprise the 400 MHz NMR, HR-Q-TOF mass spectrometer, DSC and UPLCs in addition to all of the most common equipment and techniques. The new instrument…
Cerbios-Pharma successfully passes SwissMedic inspection of its innovative ADCs conjugation suite
LUGANO, December 20th, 2019 • Cerbios is proud to announce successful SwissMedic authorization of its new cGMP bioconjugation suite for up-to commercial scale manufacturing of Antibody Drug Conjugates (ADCs). “The suite further expands Cerbios’ ADCs capacities and consolidates Cerbios commitment to provide best-in-class bioconjugation services for its partners worldwide” says Matteo Piazza Cerbios- Pharma BD…
Cerbios Appoints Claudio Pozzoli as Chief Operation Officer (COO) and Alberto Terraneo as New R&D Director
LUGANO, October 1st, 2019 • Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce that Mr. Claudio Pozzoli has been promoted as Chief Operation Officer (COO) and Alberto Terraneo is our new R&D Director. Fausto Vellani (the former COO) has moved to the sister company, strengthening a team that is already achieving excellent results and…
Approaching payload process development using QBD
LUGANO, March 18, 2019 • Thomas Matt, Senior Manager R&D Chemical Division at Cerbios, looks at some practical experiences in projects for ADC payloads. “During all stages of R&D activities, a process has to be developed, while also considering the containment system required and the design of the plant, so as to ensure reproducible manufacturing, of…
Moving along with ADCs: a CDMO perspective
LUGANO, February 15, 2019 • Vitor Sousa, Senior Manager of R&D Biological Division at Cerbios, talks about the challenges that a CDMO has to solve while developing a robust and scalable process ready for cGMP production for clinical trials and later on for commercial supply. “Antibody-drug conjugates (ADCs) for oncology therapies are composed of an antibody…
Cerbios further invests in its High Potency APIs manufacturing capacity
LUGANO, January 18, 2019 • Cerbios-Pharma SA (from now on “Cerbios”) board of directors has approved the detailed design and budget for the installation in its High Potency Active Ingredients (HPAIs) dedicated building of a new production line able to accommodate larger volumes and batch size. Cerbios is active in the HPAI arena since 1993 with…
Cerbios appoints Francesca Scarpitta as new Director strengthening its High Potency API manufacturing team
LUGANO, December 1st, 2018 • Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce that Dr. Francesca Scarpitta has joined our team as Director of our High Potency Active Ingredients (HPAIs) Production units. Cerbios is active in the HPAI arena since 1993, when the development of the first HPAI of category 4 (OEL<3ng/m3) started. In…
Lipidor: First Patient In for Phase III trials of new high- comfort, high-control anti-psoriasis spray
LUGANO, October 4th, 2018 • Psoriasis is a chronic disease affecting 2-4% of the world’s population. A new anti-psoriasis spray now in phase III trial offers more comfort to patients, and improves dose control. The first patient has now entered the trial. Lipidor’s Calcipotriol Spray is being evaluated over 8 weeks of treatment in a randomized…
Cerbios and IRB collaborate on developing antibodies targeted at Leukemia cells
LUGANO, October 2nd, 2018 • The Institute for Research in Biomedicine (IRB-USI, Bellinzona, www.irb.ch), active in human immunology research, and Cerbios-Pharma SA (Barbengo, Lugano), a company active in developing and producing active pharmaceutical ingredients (API), have started collaborating to develop Antibodies’ derivatives to treat Acute Myeloid Leukemia (AML), which makes it possible to target leukemia cells…
USA Ambassador visit to Cerbios-Pharma SA
Lugano/Bern, September 7, 2018 • On September 7, Cerbios was honored by the visit of the US Ambassador to Switzerland and Liechtenstein, Edward McMullen Jr. Aim of the visit of the Ambassador was to meet Cerbios’ top management and shareholder in order to have a better view and understanding of Cerbios’ ongoing and future activities in the…
E. Faecium SF68®: a model for efficacy & safety for pharmaceutical probiotics
LUGANO, April 19th, 2018 • Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce the publication of a comprehensive review on its proprietary Probiotic Active Ingredient E. faecium SF68® (SF68®). In an article, published in the Scientific Journal “Beneficial Microbes”, extensive information is provided on the efficacy and safety of SF68® supported by well established scientific and surveillance…
Cerbios successfully passes a general FDA cGMP inspection
LUGANO, April 17th, 2018 • It is with pleasure that we announce that on Friday the 27th of April 2018, Cerbios-Pharma SA (from now on CERBIOS) successfully passed a general FDA GMP inspection. Originally, the inspection was scheduled to last five days. Due to the excellent results, the inspector decided to close the audit in the middle of…
People on the move: Cerbios appoints Denis Angioletti as new Chief Commercial Officer (CCO) and Francesca Nembri as new Qualified Person
LUGANO, June 1st, 2017 • Cerbios-Pharma SA is pleased to announce that Mr. Denis Angioletti has joined our team as Chief Commercial Officer and Francesca Nembri is our new Qualified Person and QA/DRA Director. Andrea Tam (former CCO) has been promoted to CEO of a Cerbios’ sister company and Clarissa Gobetti (former QP) has also…
AKVANO spray delivery system for topical application can be fine-tuned for fast or slow release
Stockholm/Lugano, April 25th, 2017 • It is a pleasure to share the latest diffusion study results on the AKVANO® drug delivery system developed and owned by our partner Lipidor AB (from now on LIPIDOR). Results from the new in vitro permeation experiments, which have been performed on ketoprofen, diclofenac diethylamine and diclofenac sodium formulations in…
Claudio Pozzoli promoted to Chief Scientific Officer (CSO)
LUGANO, January 1st, 2017 • Following a corporate restructuring and the streamlining of operations at Cerbios-Pharma SA (from now on CERBIOS), we are proud to announce the promotion of Claudio Pozzoli to the position of Chief Scientific Officer (CSO). Claudio Pozzoli will lead the newly created R&D Division, which includes both divisions: Chemical and Biological.…
